This CE activity is intended for endocrinologists and primary care clinicians including NPs, PAs, residents, fellows, nurses, pharmacists, diabetes educators, and other allied professionals who provide care for individuals with T1D or T2D eligible for or treated with MTI.
Medical Learning Institute, Inc. (MLI) designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.
Commercial Support Statement
This activity is supported by an educational grant from Lilly.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Juan Pablo Frias, MD, National Research Institute, Los Angeles, CA
Juan Pablo Frias, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 89Bio, Akero, Altimmune, Axcella Health, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, Eli Lilly, Gilead, Merck, Metacrine, Novo Nordisk, Pfizer, Sanofi
Grant/Research Support from Akero, Abbvie, AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Intercept, Janssen, Madrigal, Merck, Metacrine, NorthSea, Novartis, Novo Nordisk, Oramed, Pfizer, Poxil, Sanofi
Speakers Bureau participant with Merck, Novo Nordisk, Sanofi
Dhiren Patel, PharmD, CDE, BC-ADM, BCACP, Massachusetts College of Pharmacy, Boston, MA
Dhiren Patel, PharmD, CDE, BC-ADM, BCACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott, Amarin, Astra Zeneca, Bayer, Boehringer Ingelheim, Dexcom, Insulet, Lilly, Merck, Novo Nordisk, Sanofi, Xeris, Zealand
Speakers Bureau participant with Abbott, Amarin, Astra Zeneca, Bayer, Boehringer Ingelheim, Dexcom, Insulet, Lilly, Merck, Novo Nordisk, Sanofi, Xeris, Zealand
Jay Shubrook, DO, FACOFP, FAAFP, Touro University California, Vallejo, CA
Jay Shubrook, DO, FACOFP, FAAFP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astra Zeneca, Bayer, Eli Lilly
Katherine H Whitmire, NP-c, BC-ADM, CDCES, Southwest Medical Associates, Las Vegas, NV
Katherine H Whitmire, NP-c, BC-ADM, CDCES has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc, the Endocrine Society and National Committee for Quality Assurance, does not have any relevant financial relationships to disclose with ineligible companies unless listed below.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Disclosure of Unlabled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
About this Activity
Medical Learning Institute, Inc. and are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. (The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.)
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Once submitted, the certificate will be automatically generated as a PDF online.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy/
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.
If you have questions regarding the receipt of your certificate, please contact Nicole Dane, via email at email@example.com